Page last updated: 2024-11-04

ditercalinium

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ditercalinium: structure given in first source; RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3119
CHEMBL ID1182165
MeSH IDM0126204

Synonyms (20)

Synonym
CHEMBL1182165
ditercalinium cation
ditercalinium ion
nsc335153
2,2'-([4,4'-bipiperidine]-1,1'-diyldi-2,1-ethanediyl)bis[10-methoxy-7-pyrido[4,3-c]carbazolium, dichloride
10-methoxy-2-[2-[4-[1-[2-(10-methoxy-7h-pyrido[4,3-c]carbazol-2-ium-2-yl)ethyl]-4-piperidyl]-1-piperidyl]ethyl]-7h-pyrido[4,3-c]carbazol-2-ium
82765-18-2
ditercalinium
NEURO_000207
7h-pyrido(4,3-c)carbazolium, 2,2'-((4,4'-bipiperidine)-1,1'-diyldi-2,1-ethanediyl)bis(10-methoxy-
2,2'-((4,4'-bipiperidine)-1,1'-diyldi-2,1-ethanediyl)bis(10-methoxy-7h-pyrido(4,3-c)carbazolium)
ditercalinio [spanish]
2,2'-(4,4'-bipiperidine-1,1'-diyldiethane-2,1-diyl)bis(10-methoxy-7h-pyrido[4,3-c]carbazol-2-ium)
ditercalinio
vfs4zuk33p ,
unii-vfs4zuk33p
2,2'-((4,4'-bipiperidine)-1,1'-diyldiethylene)bis(10-methoxy-7h-pyrido(4,3-c)carbazolium)
Q27291812
DTXSID50868314
2,2'-[[4,4'-bipiperidine]-1,1'-diyldi(ethane-2,1-diyl)]bis(10-methoxy-7h-pyrido[4,3-c]carbazol-2-ium)

Research Excerpts

Overview

Ditercalinium (NSC 366241) is a 7H-pyrido[4,3-c]carbazole dimer. It has a diethylbipiperidine rigid chain linking the two heterocyclic rings.

ExcerptReferenceRelevance
"Ditercalinium (NSC 366241) is a 7H-pyrido[4,3-c]carbazole dimer with a diethylbipiperidine rigid chain linking the two heterocyclic rings. "( Synthesis and biological activity of new dimers in the 7H-pyrido[4,3-c] carbazole antitumor series.
Barsi, MC; Garbay-Jaureguiberry, C; Jacquemin-Sablon, A; Le Pecq, JB; Roques, BP, 1992
)
1.73
"Ditercalinium is a synthetic anticancer drug that binds to DNA by bis-intercalation and activates DNA repair processes. "( Drug-induced DNA repair: X-ray structure of a DNA-ditercalinium complex.
Chen, SL; Egli, M; Gao, Q; Quigley, GJ; Rabinovich, D; Rich, A; Williams, LD, 1991
)
1.98
"Ditercalinium (NSC 335153) is a novel 7H-pyridocarbazole dimer in which the two monomers are joined by a rigid bis(ethylpiperidinyl)-linking chain producing a molecule capable of bisintercalation into DNA with extremely high affinity. "( Cytokinetic effects of bifunctional antitumor intercalator ditercalinium on Friend erythroleukemia cells.
Bueti, C; Darzynkiewicz, Z; Melamed, MR; Traganos, F, 1987
)
1.96

Treatment

Ditercalinium treatment of Escherichia coli causes cell death by provoking malfunction of the (A)BC exinuclease excision DNA repair system. DiterCalinium Treatment of L1210 leukemic mouse cells leads to a specific elimination of mitochondrial DNA detected by DNA-DNA hybridization.

ExcerptReferenceRelevance
"Ditercalinium treatment of Escherichia coli causes cell death by provoking malfunction of the (A)BC exinuclease excision DNA repair system."( DNA-ditercalinium interactions: implications for recognition of damaged DNA.
Gao, Q; Williams, LD, 1992
)
1.56
"Ditercalinium treatment of L1210 leukemic mouse cells leads to a specific elimination of mitochondrial DNA detected by DNA-DNA hybridization."( Selective loss of mitochondrial DNA after treatment of cells with ditercalinium (NSC 335153), an antitumor bis-intercalating agent.
Coulaud, D; Le Pecq, JB; Roques, BP; Segal-Bendirdjian, E, 1988
)
1.23
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (45)

TimeframeStudies, This Drug (%)All Drugs %
pre-199023 (51.11)18.7374
1990's15 (33.33)18.2507
2000's5 (11.11)29.6817
2010's1 (2.22)24.3611
2020's1 (2.22)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 18.25

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index18.25 (24.57)
Research Supply Index3.85 (2.92)
Research Growth Index4.47 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (18.25)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (2.17%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other45 (97.83%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]